Simplified novel prognostic score for real-life older adults with multiple myeloma—registry-based analysis
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Hematology"
DOI: 10.1007/s00277-018-3568-2
Abstract: The main goal was to find a simple prognostic to evaluate overall survival of patients older than 65 years of age with myeloma. Retrospective registry-based analysis from the Registry of Monoclonal Gammopathies was conducted. Patients over… read more here.
Keywords: registry based; intermediate poor; good intermediate; intermediate good ... See more keywords
A Suggested Prognostic Reclassification of Intermediate and Poor‐Risk Nonseminomatous Germ Cell Tumors
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Genitourinary Cancer"
DOI: 10.1016/j.clgc.2016.07.022
Abstract: Micro‐Abstract In a large series of intermediate and poor risk nonseminomatous germ‐cell tumors we were able to identify new prognostic factors and to construct an improved risk classification system. Fewer cycles of cisplatin, etoposide, and… read more here.
Keywords: poor risk; risk; intermediate poor; germ cell ... See more keywords
Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of medical economics"
DOI: 10.1080/13696998.2021.1883034
Abstract: BACKGROUND Considering clinical benefits of new combination therapies for metastatic renal-cell carcinoma (mRCC), this study aims to calculate the number needed to treat (NTT) and the cost of preventing an event (COPE) for pembrolizumab plus… read more here.
Keywords: poor risk; intermediate poor; line; first line ... See more keywords
342 A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk
Sign Up to like & getrecommendations! Published in 2020 at "Journal for ImmunoTherapy of Cancer"
DOI: 10.1136/jitc-2020-sitc2020.0342
Abstract: Background Cabozantinib (C) inhibits tyrosine kinases involved in tumor growth, angiogenesis, and immune regulation, including MET, VEGFR, and TAM kinases (Tyro3, AXL, MER), and may promote an immune-permissive tumor environment, resulting in enhanced response to… read more here.
Keywords: poor risk; combination; intermediate poor; previously untreated ... See more keywords
Analysis of a Systemic Inflammatory Biomarker in Advanced Bile Tract Carcinoma Treated with Anti-PD-1 Therapy: Prognostic and Predictive Significance of Lung Immune Prognostic Index Score
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology"
DOI: 10.1155/2022/1427779
Abstract: Background The application of immunotherapy is gradually increasing in advanced bile tract carcinoma (BTC), but only some patients could benefit from it. Validated biomarkers can screen out the beneficiaries. Therefore, the objective of this research… read more here.
Keywords: lipi; intermediate poor; group; advanced bile ... See more keywords
Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours
Sign Up to like & getrecommendations! Published in 2018 at "BMC Cancer"
DOI: 10.1186/s12885-018-4745-3
Abstract: BackgroundBleomycin, etoposide, and cisplatin (BEP) chemotherapy administered every 3 weeks for 4 cycles remains the standard first line treatment for patients with intermediate- and poor-risk metastatic germ cell tumours (GCTs). Administering standard chemotherapy 2-weekly rather than 3-weekly,… read more here.
Keywords: chemotherapy; poor risk; trial; intermediate poor ... See more keywords
Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.4508
Abstract: 4508Background: A prior single arm phase 2 trial of TIP in intermediate- and poor-risk GCT found superior rates of response, progression-free survival (PFS), and overall survival (OS) compared to h... read more here.
Keywords: poor risk; intermediate poor; cisplatin; tip ... See more keywords
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.4500
Abstract: 4500 Background: In KEYNOTE-426, pembro + axi significantly improved OS (HR 0.53, P < .0001), PFS (HR 0.69, P = .0001), and ORR (59.3% vs 35.7%, P < .0001) vs sunitinib and had manageable toxicity… read more here.
Keywords: poor risk; pembro axi; risk; intermediate poor ... See more keywords
Preoperative lung immune prognostic index predicts survival in patients with pancreatic cancer undergoing radical resection
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Surgery"
DOI: 10.3389/fsurg.2022.1002075
Abstract: Background Lung immune prognostic index (LIPI), a combination of derived neutrophil-to-lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH), is currently attracting considerable interest as a potential prognostic indicator in many malignancies. Our study aimed to investigate… read more here.
Keywords: undergoing radical; lipi intermediate; resection; radical resection ... See more keywords